New approaches to neuroprotective drug development

Stroke

Volumn 42, Issue SUPPL. 1, 2011, Pages

  Fisher, Marc ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Neuroprotection; Treatment

Indexed keywords

CITICOLINE; GRANULOCYTE COLONY STIMULATING FACTOR; MAGNESIUM; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; NEUROPROTECTIVE AGENT;

BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; FIBRINOLYTIC THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; STROKE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; PATHOLOGY; REPERFUSION; REVIEW;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEUROPROTECTIVE AGENTS; REPERFUSION; REPERFUSION INJURY; STROKE;

EID: 79952117976     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.592394     Document Type: Conference Paper

References (26)

1. Lo E, Dalkara T, Moskowitz M. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4:399-415. (Pubitemid 37280178)
2. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab. 2007;27:435-451.
3. Bang OY, Saver JL, Buck BH, Alger JR, Starkman S, Ovbiagele B, Kim D, Jahan R, Duckwiler GR, Yoon SR, Vinuela F, Liebeskind DS, UCLA Collateral Investigator. Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psych. 2008;79:625-629. (Pubitemid 351829431)
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Lees KR, Medezhriz T, Schneider D, Von Kumar R, Wahlgren N, Toni D (for the ECASS Investigators). Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
6. Fisher M. The ischemic penumbra: a new opportunity for neuroprotection. Cerebrovasc Dis. 2006;(suppl 2):64-70.
7. Hossman KA. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol. 2006;26:1055-1081.
8. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new directions. Stroke. 2002;33:2123-2136. (Pubitemid 34840080)
9. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.
10. Fisher M, Feuerstein GZ, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH (for the STAIR group). Update of the Stroke Therapy Academic Industry Roundtable preclinical recommendations. Stroke. 2009;40: 2244-2250.
11. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477. (Pubitemid 43358067)
12. Sicard KM, Fisher M. Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009;14:1-10.
13. Fisher M, Cheung K, Howard G, Warach S. New pathways for evaluating potential acute stroke therapies. Int Stroke J. 2006;1:52-58.
14. Kleindorfer D, Xu Y, Moomaw. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke. 2009;40: 3580-3584.
15. Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal: how brain cells die after stroke. Stroke. 2005;36:189-192. (Pubitemid 40170779)
16. Henninger N, Bouley J, Nelligan J, Sicard KM, Fisher M. Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2007;27:1632-1642. (Pubitemid 47301449)
17. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hyperoxia and late tPA in a rat embolic stroke model. J Cereb Blood Flow Metab. 2009;29:119-129.
18. Bratane B, Bouley J, Schneider A, Bastan B, Henninger N, Fisher M. Granulocyte colony stimulating factor delays mismatch evolution and reduces final infarct volume in permanent suture and embolic rat focal cerebral ischemia models. Stroke. 2009;40:3102-3106.
19. Yanes A, Haley T, Pierce B, Gordon M, Filip B, Lee M, Cho M, Starkman S, Saver J, on behalf of FAST MAG Investigators and Staff. Breaking traditional study time barriers: a descriptive review of demographic variables and unique early observations seen in a prehospital stroke study. Stroke. 2008;39:590. Abstract.
20. Warach SW, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood- brain barrier disruption Stroke. 2004;35: 2659-2661. (Pubitemid 39458362)
21. Li F, Liu KF, Silva, Helmer KG, Omae T, Fenstermacher JD, Sotak CH, Fisher M. Secondary decline in apparent diffusion coefficient and neurological outcome after a short period of focal brain ischemia in rats. Ann Neurol. 2000;48:236-244. (Pubitemid 30617043)
22. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, Gobin PY, Johan R, Vespa P, Kalafut M, Alger JR. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462-469. (Pubitemid 30194602)
23. Schabitz WR, Schneider A. New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci. 2007;28:157-161. (Pubitemid 46483721)
24. Minnerup J, heidrich J, Wellmann J, Rogalewski A, Schnieder A, Schabitz WR. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal ischemia. Stroke. 2008;39: 1855-1861.
25. Secades JJ, Lorenzo JL. Citicoline: pharmacological profile and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006;28(Suppl B):1-56. (Pubitemid 44569736)
26. Clark WM. Efficacy of citicoline as acute ischemic stroke therapy. Expert Opin on Pharmacother. 2009;10:839-846.